Health department cancels the Licence of Path lab for issuing wrong dengue report

People trust labs and whole doctor treatment will depend upon the basic test reports. But what will happen, if labs send the wrong report and this can be dangerous for a person undergoing treatment? Surprise inspections help the health department to know about how the tests and reports were prepared. In medical treatments, there is nothing like transparency and anyone can fool people.

When health department inspection team found a private pathology lab issuing false dengue positive reports, then they inspected the whole lab and found that issued reports given by the pathology stated that dengue test was done through Enzyme-Linked Immunosorbent Assay (ELISA), no equipment used for the test was present in the lab. 

And officials found that staff, even not aware of how to use the ELISA method for testing samples. Pathologist Dr Rajesh headed the four-member team and started inspection to find discrepancies in dengue positive reports issued by the pathology.

Dr KP Tripathi, in charge of the vector-borne disease control unit, said that the anomalies in the reports were detected during an audit of patients who died due to dengue in the city.  Recently, a 34-year-old woman who recently died due to high fever and the pathology had issued a dengue positive test report to her.

Narendra Agarwal, Chief medical officer said that An FIR will be lodged against the pathology as if wrong reports delivered then wrong treatment may lead the patient to death. This type of fake reports endangering people’s health as the centre may have issued fake reports to other patients as well. After inspecting the wrong dengue fever reports, health dept cancels the licence of the pathology lab.

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India